Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$3.00 USD
-0.05 (-1.64%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.96 -0.04 (-1.33%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNGO 3.00 -0.05(-1.64%)
Will BNGO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNGO
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
Other News for BNGO
Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference | BNGO Stock News
Bionano Genomics (BNGO) Unveils Enhanced Genomic Analysis Software
Bionano Genomics announces release of latest versions of its VIA, Solve
Bionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, ...
Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on ...